

Nuevas herramientas en el tratamiento
adjuvante en la enfermedad Her2+

HER2+ BREAST CANCER




Instituto Zucunino

Fundación Marie Curie

HER2+ Breast Cancer

- More nodal involvement (>3 positive nodes)¹
- Tumor profile: >2 cm, grade 3, high mitosis, lymphoid infiltration¹
- Significantly fewer PgR+ tumors¹
- Higher incidence of CNS metastases²
- Patients more likely to be premenopausal¹
- Differential sensitivity to CT and HT
- Distinct gene expression pattern: differs from basal- and luminal-like breast cancer subgroups³



1. Ménard et al. *Clin Cancer Res.* 2002;8:520.

2. Gori et al. *Oncologist.* 2007;12:766.

3. Sorlie et al. *Proc Natl Acad Sci U S A.* 2003;100:8418.

ORIGINAL ARTICLE

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine J. Piccart-Gebhart, M.D., Ph.D., Marion Procter, M.Sci., Brian Leyland-Jones, M.D., Ph.D., Aron Goldhirsch, M.D., Michael Untch, M.D., Ian Smith, M.D., Luca Gianni, M.D., Jose Baselga, M.D., Richard Bell, M.D., Christian Jackisch, M.D., David Cameron, M.D., Mitch Dowsett, Ph.D., et al.,
for the Herceptin Adjuvant (HERA) Trial Study Team

Article

Figures/Media

October 20, 2005

N Engl J Med 2005; 353:1659-1672

DOI: 10.1056/NEJMoa052306

ORIGINAL ARTICLE

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, M.D., Edith A. Perez, M.D., John Bryant, Ph.D., Vera J. Suman, Ph.D., Charles E. Geyer, Jr., M.D., Nancy E. Davidson, M.D., Elizabeth Tan-Chiu, M.D., Silvana Martino, D.O., Soonmyung Paik, M.D., Peter A. Kaufman, M.D., Sandra M. Swain, M.D., Thomas M. Pisansky, M.D.,

et al.


Instituto Zúñino

Fundación Marie Curie

[Article](#) [Figures/Media](#)


October 20, 2005

N Engl J Med 2005; 353:1673-1684




AI, aromatase inhibitor; CMF, cyclophosphamide, methotrexate and fluorouracil; HR, hazard ratio; RR, risk ratio.

The EGFR (erbB) family



- Todos los pacientes requeriran quimioterapia agresiva?
- Podremos minimizar la quimioterapia?
- Podremos elimiar la quimioterapia?
- Podremos identificar los tumores que solo requieran tratamientos anti Her?



Instituto Zunino

Fundación Marie Curie

HER2+ BREAST CANCER

